Skip to content
An Initiative of AVAC
Search
Back to Resource Library

PURPOSE 1 Summary

5 August 2024

This factsheet provides a summary of the PURPOSE 1 phase III clinical trial of lenacapavir for PrEP and F/TAF for cisgender women taking place in South Africa and Uganda.

Topic(s): Research

Product(s): F/TAF, Lenacapavir, Oral PrEP

Population(s): Cisgender Women

Region(s): Sub-Saharan Africa

Format(s): Factsheet

Countries: South Africa, Uganda

Source(s): Gilead

Type: Document

Download

Featured Resources

Document

The Long Wait for Long-acting HIV Prevention and Treatment Formulations

This commentary from The Lancet HIV calls on WHO, financial donors, manufacturers, and governments to take coordinated action to make long-acting HIV prevention and treatment available at scale in lower and middle income countries.
Spreadsheet

2024 Q2 Global PrEP Tracker

AVAC’s Global PrEP Tracker offers two views on PrEP uptake around the world. Visit data.prepwatch.org for a dynamic map-based tool to explore trends in oral PrEP use globally as countries introduce and scale up PrEP programs. For insights on the full scope of PrEP use around the world, the PrEP Tracker as a spreadsheet offers…
External Link

Client Experiences with “Dynamic Choice Prevention,” a Model for Flexible Patient-centred HIV Prevention Delivery in Rural Eastern Africa

This article from Journal of the International AIDS Society discusses client experiences of a dynamic choice model for HIV prevention piloted in Kenya and Uganda under the SEARCH study, where clients were supported to select HIV prevention method, testing mode, and service delivery channel from a range of options.
Document

Online Pharmacy PrEP and PEP: Technical considerations and learnings from Kenya

This document, developed by PATH, is intended as a how-to implementation guide for providing oral pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) via online pharmacy service delivery (ePrEP/ePEP) based on learnings and evidence from the ePrEP Kenya pilot study that ran from October 2022 through July 2024. The guide was developed to support ministries of…
External Link

Women’s Preferences for HIV Prevention Service Delivery in Pharmacies during Pregnancy in Western Kenya: A discrete choice experiment

This article from Journal of the International AIDS Society describes the results of a discrete choice experiment to evaluate where and how pregnant and lactating people in western Kenya preferred to access HIV prevention services, including PrEP.
External Link

Investigating the Effectiveness of Web-based HIV Self-test Distribution and Linkage to HIV Treatment and PrEP among Groups at Elevated Risk of HIV in Viet Nam Provinces: A mixed-methods analysis of implementation from pilot to scale-up

This article from Journal of the International AIDS Society describes the impact of a web-based HIV self-testing intervention, including linking those who tested negative to PrEP services, in Vietnam.
Document

Pre-Exposure Prophylaxis and Adolescent Girls and Young Women in Eastern and Southern Africa: The latest insights

Eastern and southern Africa (ESA) is the world’s most heavily HIV-impacted region, with adolescent girls and young women (AGYW) disproportionately affected. To support the scale-up of PrEP amongst AGYW in ESA, in September 2021 UNICEF and partners released the implementation brief “Improving the Quality of Pre-Exposure Prophylaxis Implementation for Adolescent Girls and Young Women in…
External Link

WHO Implementation Tool for Pre-Exposure Prophylaxis (PrEP) of HIV Infection

The WHO has developed this series of modules to support the implementation of PrEP among a range of populations in different settings.
Document

The Lens on LEN

In late June 2024, Gilead Sciences announced an early review of the data of the PURPOSE 1 trial by an independent monitoring board, which found that injectable lenacapavir (LEN) provided as prevention was safe and highly effective against HIV. The product is being tested among 5,300 HIV-negative cisgender women ages 16-25 in Uganda and South…
External Link

Low Selection of HIV PrEP Refills at Private Pharmacies among Clients who Initiated PrEP at Public Clinics: Findings from a mixed-methods study in Kenya

This article from BMC Health Services Research describes the impact of a pilot project to permit oral PrEP users to obtain refills at private pharmacies for an additional fee.